jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Uterus Cervix Biopsy-XL

Biopsy
image

Report in 288Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Diagnose benign or malignant diseases affecting female reproductive organs

₹888₹1,269

30% OFF

Uterus Cervix Biopsy-XL - Comprehensive Medical Test Information Guide

  • Why is it done?
    • Test Purpose: The Uterus Cervix Biopsy-XL is a diagnostic procedure that obtains tissue samples from the cervix for microscopic examination to detect abnormal or cancerous cells, infections, inflammatory conditions, and other pathological processes.
    • Primary Indications for Ordering: Abnormal Pap smear or HPV test results requiring tissue confirmation; persistent cervical inflammation or bleeding; visible cervical lesions, masses, or polyps; evaluation of abnormal vaginal bleeding; suspected cervical dysplasia or carcinoma; atypical cervical findings on colposcopy; immunocompromised patients with concerning cervical findings.
    • Typical Timing and Circumstances: Performed during colposcopy when abnormal tissue is visualized; usually scheduled in outpatient gynecology settings; best performed during the follicular phase of menstrual cycle (before ovulation); not recommended during menstruation or pregnancy unless clinically urgent; may be performed as follow-up to abnormal screening results or as part of diagnostic workup for persistent gynecological symptoms.
  • Normal Range
    • Normal Finding: Benign cervical tissue with normal squamous epithelium; absence of dysplasia, malignancy, or significant inflammation.
    • Reference Values and Interpretation:
      • Negative/Normal: No dysplasia, no malignancy detected (NILM - Negative for Intraepithelial Lesion or Malignancy); tissue shows normal mature squamous cells with appropriate maturation; no evidence of HPV-related changes; inflammation minimal or absent.
      • Positive/Abnormal Results: Cervical Intraepithelial Neoplasia (CIN) grades 1, 2, or 3; squamous cell carcinoma; adenocarcinoma; cervical polyps; cervical fibroids or other benign lesions; evidence of HPV infection; chronic cervicitis or cervical inflammation.
      • Borderline/Uncertain Results: Atypical Squamous Cells of Undetermined Significance (ASCUS); Atypical Glandular Cells (AGC); tissue showing reactive changes or metaplasia that may mimic dysplasia; requires clinical correlation and possible repeat sampling.
    • Units of Measurement: Histopathological grading using standardized classification systems (CIN grading, WHO classification, Bethesda System); results reported as descriptive pathology findings rather than numerical values.
  • Interpretation
    • CIN Grade 1 (Mild Dysplasia): Abnormal cells confined to lower one-third of epithelium; increased nuclear-to-cytoplasmic ratio; usually HPV-related; many cases regress spontaneously; requires monitoring with repeat cytology or colposcopy in 6-12 months.
    • CIN Grade 2 (Moderate Dysplasia): Abnormal cells extend to lower two-thirds of epithelium; more pronounced cellular atypia; higher risk of progression to malignancy; typically requires excisional or ablative treatment (LEEP, laser conization, or cold knife conization).
    • CIN Grade 3 (Severe Dysplasia/Carcinoma in Situ): Abnormal cells occupy full thickness of epithelium; high-grade lesion with significant risk of progression to invasive cancer if untreated; requires immediate excisional treatment with adequate margins; close follow-up and surveillance essential.
    • Squamous Cell Carcinoma: Invasive malignant cells crossing basement membrane into stroma; indicates invasive cancer requiring immediate referral to oncology; staging workup needed; treatment options include surgery, radiation, chemotherapy, or combination therapy.
    • Adenocarcinoma: Malignant glandular cells; more aggressive than squamous carcinomas; often diagnosed at later stages; requires immediate oncologic consultation; higher mortality rate; treatment typically involves radical hysterectomy with pelvic lymph node dissection.
    • Benign Lesions (Polyps, Fibroids): Non-malignant growths; may cause vaginal bleeding or discharge; treatment depends on symptoms and size; often managed with office removal or observation.
    • Chronic Cervicitis/Inflammation: Persistent inflammation of cervical tissue; may indicate infection, irritation, or reactive changes; treatment based on underlying cause (antibiotics for infection, removal of irritant); usually benign but requires evaluation for underlying pathology.
    • Factors Affecting Results: Adequacy of tissue sample; timing of biopsy in menstrual cycle; presence of inflammation obscuring findings; immunosuppression affecting lesion progression; HPV status and type; smoking history; oral contraceptive use; prior cervical treatments; specimen preservation and processing quality.
  • Associated Organs
    • Primary Organ System: Female reproductive system; specifically the cervix (lower portion of uterus); also impacts uterus, vagina, and external genitalia; related to endocrine system (hormonal influences); lymphatic system (metastatic spread potential).
    • Medical Conditions Associated with Abnormal Results:
      • Cervical dysplasia (CIN stages 1-3)
      • Cervical cancer (squamous cell and adenocarcinoma)
      • Human Papillomavirus (HPV) infection
      • Chronic cervicitis and inflammatory conditions
      • Cervical polyps and benign neoplasms
      • Infectious cervicitis (chlamydia, gonorrhea, herpes simplex)
      • Cervical fibroids and endometriosis
    • Diseases This Test Helps Diagnose or Monitor:
      • Cervical Cancer Detection: Definitive diagnosis through histopathological examination; determines grade and extent of malignancy for staging and treatment planning.
      • HPV-Related Lesion Monitoring: Tracks progression or regression of HPV-induced dysplasia; assists in determining need for treatment intensification.
      • Post-Treatment Surveillance: Evaluates adequacy of previous treatment; detects recurrent or residual dysplasia; identifies adequacy of surgical margins.
    • Potential Complications and Risks Associated with Abnormal Results:
      • Progression to Invasive Cancer: CIN lesions, if left untreated, may progress to invasive carcinoma over 5-10 years; higher risk with high-grade lesions (CIN 2-3) and persistent HPV infection.
      • Metastatic Disease: Advanced cervical cancer may spread to pelvic lymph nodes, bladder, rectum, liver, and lungs; compromises survival outcomes if not detected early.
      • Fertility and Reproductive Complications: Treatment of high-grade lesions (conization, LEEP) may cause cervical stenosis, scarring, or preterm birth in future pregnancies; radical hysterectomy for cancer eliminates fertility.
      • Vaginal and Pelvic Complications: Chronic pelvic pain, vaginal stenosis, rectovaginal fistula, or urinary tract complications may result from advanced disease or aggressive treatment.
      • Systemic Effects: Advanced malignancy causes constitutional symptoms (weight loss, fatigue); chemotherapy and radiation therapy produce significant side effects; impaired quality of life and psychological impact.
  • Follow-up Tests
    • Based on CIN Grade 1 Results: Repeat cytology (Pap smear) at 6 months; HPV testing to guide management; colposcopy if repeat cytology abnormal; may regress without treatment; follow-up surveillance for 24-30 months.
    • Based on CIN Grade 2-3 Results: Immediate excisional procedure recommended (LEEP, cold knife conization, or laser conization); endocervical sampling to assess margins; repeat cytology at 3-6 months post-treatment; colposcopy for surveillance; HPV testing at 6-12 months.
    • Based on Malignancy Findings:
      • MRI imaging of pelvis for staging and extent of disease
      • CT chest/abdomen/pelvis for detection of metastatic disease
      • PET-CT scanning to identify metastatic lesions
      • Cystoscopy and proctoscopy if bladder/rectal involvement suspected
      • Oncology consultation for treatment planning
      • Tumor marker testing (SCC antigen, CEA) as baseline and for monitoring response to therapy
    • Long-term Monitoring and Follow-up Schedule:
      • Post-Treatment CIN 1: Annual cytology for 25-30 years or colposcopy at 3-6 month intervals until two consecutive negative results.
      • Post-Treatment CIN 2-3: Colposcopy at 4-6 weeks post-treatment; cytology and HPV co-testing at 6 months; continued surveillance for minimum 20-30 years.
      • Post-Cancer Treatment: Imaging surveillance (MRI/CT) every 3-6 months for first 2-3 years; physical examination and symptoms assessment at each visit; tumor markers at routine intervals; long-term follow-up varies by cancer stage and treatment type.
    • Complementary Tests for Additional Information:
      • HPV DNA/RNA testing to confirm HPV status and genotype
      • Immunohistochemistry (p16, Ki-67) for better dysplasia grading
      • Repeat Pap smear cytology for correlation with biopsy findings
      • Endocervical curettage when margins are concerning
      • Molecular testing for HPV types 16/18 (high-risk types)
  • Fasting Required?
    • Fasting Requirement: NO - Fasting is not required for cervical biopsy. This is a local tissue sampling procedure and does not require systemic preparation related to food or fluid intake.
    • Pre-Procedure Preparation Instructions:
      • Timing: Schedule biopsy during follicular phase of menstrual cycle (days 5-20); avoid scheduling during menstruation or immediately after ovulation (days 21-28); if possible, avoid scheduling in luteal phase to minimize cervical friability.
      • Personal Hygiene: Shower or bathe before procedure; avoid douching for 48 hours prior to biopsy; avoid tampons, pessaries, or vaginal medications for 48 hours before appointment.
      • Sexual Activity: Avoid sexual intercourse for 48 hours prior to procedure; abstinence reduces cervical irritation and inflammation.
      • Contraceptive Devices: Remove any IUD (intrauterine device) if it interferes with visualization or safe biopsy access; cervical cap or diaphragm should be removed before procedure.
    • Medications - Specific Instructions:
      • Anticoagulants: Continue warfarin (Coumadin) as prescribed; may need to discontinue or modify clopidogrel (Plavix), ticlopidine (Ticlid), or other antiplatelet agents 3-5 days prior; consult with prescribing physician; aspirin continuation usually acceptable.
      • NSAIDs: Avoid ibuprofen, naproxen, and other NSAIDs for 3-7 days prior if possible to reduce bleeding risk; acetaminophen is acceptable for pain management.
      • Oral Contraceptives: Continue regular dose as scheduled; does not affect biopsy procedure or results.
      • Analgesics: May take acetaminophen (Tylenol) 500-1000 mg or ibuprofen (Advil) 200-400 mg approximately 30 minutes before procedure for cramping management; discuss preferences with healthcare provider.
    • Other Preparation Requirements:
      • Transportation: Although usually performed without general anesthesia, arrange for someone to drive home as mild discomfort or lightheadedness may occur; avoid driving immediately after procedure.
      • Informed Consent: Review and sign informed consent forms explaining procedure, risks, benefits, and alternatives; discuss with provider any questions or concerns.
      • Pregnancy Status: Inform provider if pregnant or suspect pregnancy; biopsy generally avoided during pregnancy unless cancer strongly suspected; if necessary, performed with extreme caution.
      • Post-Procedure Expectations: Plan to rest for remainder of day; expect mild to moderate cramping for several hours; vaginal spotting or light bleeding for 1-2 weeks is normal; avoid sexual activity, tampons, and douching for 2-4 weeks post-procedure.

How our test process works!

customers
customers